After being rebuffed several times, Cigna (CI) finally agreed to a higher $54.2 billion buyout by Anthem (ANTM) to create the nation’s largest health insurance company with more than 53 […]
CHICAGO–(BUSINESS WIRE)–A scientific paper published In the July issue of the prestigious peer-reviewed scientific Journal “Anticancer Research,” describes the properties of a food product that is reminiscent of the “super […]
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for […]
Latest Approval Expands Product Label in Canada and Further Strengthens Global Brand for Once-Daily, Dual Mechanism Antibiotic DUBLIN, IRELAND–(Marketwired – Jul 23, 2015) – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance […]
Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in […]
Merck & Co. has apparently gotten excited again about pushing the frontier with new RNA-based therapies. MRL Ventures, Merck’s early-stage biotech investment arm, has agreed to join The Baupost Group […]
Sometimes data just speaks for itself. But more often, its left to scientists and journalists to try and draw useful conclusions from complex observations. And so is the case with […]
Alzheimer’sAxovant, a drug company created by former hedge fund manager Vivek Ramaswamy, has become a battleground stock because some critics can’t believe the company’s experimental Alzheimer’s drug, RVT-101, could possibly […]
A new report finds that taking antibiotics for a common bacteria, Helicobacter pylori, reduces the occurrence of gastric cancer. For decades, doctors have understood that H. pylori infection plays a role in malignancy of […]
An appeals court ruled that Novartis AG could begin the first U.S. sales of a knockoff biotech drug on Sept. 2, a key step in efforts to contain spending on […]
